Adagene completes enrollment in Phase 2 trial of muzastotug-Keytruda combination for colorectal cancer
ADAG•Adagene completed enrollment of 60 patients in a randomized Phase 2 trial comparing muzastotug and Keytruda dosing regimens in previously treated microsatellite-stable colorectal cancer patients without liver metastases. Initial results are expected in the first half of 2027.
1. Trial enrollment complete
Adagene said it completed enrollment of 60 patients in the randomized Phase 2 trial of muzastotug combined with Merck’s Keytruda. The study compares dosing regimens in patients with previously treated microsatellite-stable colorectal cancer without liver metastases; initial results are expected in the first half of 2027 to guide dosing for a Phase 3 trial focused on overall survival.
